转移性非去势前列腺癌抗癌治疗优化:ASCO临床实践指南
该指南针对未接受或仅轻微接受睾酮抑制治疗的转移性前列腺癌患者,评估ADT联合多西他赛或阿比特龙的价值。多项随机研究显示联合治疗较ADT单药改善总生存,但两方案未直接比较,需结合体能、合并症、毒性、生活质量及费用个体化选择。
要点
- 新诊断转移性非去势前列腺癌,ADT联合多西他赛或阿比特龙较ADT单药有生存获益。
- 多西他赛获益最强证据见于de novo高瘤负荷(CHAARTED标准)患者。
- 阿比特龙在LATITUDE高风险标准和STAMPEDE转移人群中显示相似生存获益。
核心结论
- 在新诊断的转移性非去势前列腺癌中,ADT联合多西他赛或阿比特龙较ADT单药提供生存获益。
- ADT联合阿比特龙与ADT联合多西他赛尚未直接比较,不确定是否存在某一方案更优的亚组。
研究设计与样本
- 指南基于三项比较ADT单药与ADT联合多西他赛的随机研究(GETUG-AFU 15、STAMPEDE、CHAARTED)及两项比较ADT单药与ADT联合阿比特龙的研究(LATITUDE、STAMPEDE)。
主要发现
- STAMPEDE显示ADT联合多西他赛较ADT单药改善OS(HR 0.78,95%CI 0.66-0.93,n=2,962)。
- CHAARTED显示ADT联合多西他赛较ADT单药改善OS(HR 0.73,95%CI 0.59-0.89,n=790)。
- GETUG-AFU 15研究为阴性结果。
- LATITUDE显示ADT联合阿比特龙(联合泼尼松或泼尼松龙)较ADT单药改善OS(HR 0.62,95%CI 0.51-0.76,n=1,199)。
- STAMPEDE显示ADT联合阿比特龙较ADT单药改善OS(HR 0.63,95%CI 0.52-0.76,n=1,917)。
关键数值与推荐
- 推荐新诊断转移性非去势前列腺癌使用ADT联合多西他赛或阿比特龙,因较ADT单药有生存获益。
- 多西他赛获益最强证据见于de novo高瘤负荷(CHAARTED标准)转移性患者。
- 阿比特龙在LATITUDE高风险患者及STAMPEDE转移人群中显示相似生存获益。
临床怎么用
- 选择ADT联合多西他赛或阿比特龙时,应考虑化疗适应性、患者合并症、毒性谱、生活质量、药物可及性和费用。
- 多西他赛方案优先用于de novo高瘤负荷(CHAARTED标准)患者,阿比特龙方案可用于LATITUDE高风险或STAMPEDE转移人群。
局限性
- ADT联合阿比特龙与ADT联合多西他赛未经直接比较,不确定某些患者是否从某一方案获益更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This clinical practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastatic prostate cancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. Results Three prospective randomized studies (GETUG-AFU 15, STAMPEDE, and CHAARTED) examined overall survival (OS) with adding docetaxel to ADT. STAMPEDE and CHAARTED favored docetaxel (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; n = 2,962 and HR, 0.73; 95% CI, 0.59 to 0.89; n = 790, respectively). GETUG-AFU 15 was negative. LATITUDE and STAMPEDE examined the impact on OS of adding abiraterone (with prednisone or prednisolone) to ADT. LATITUDE and STAMPEDE favored abiraterone (HR, 0.62; 95% CI, 0.51 to 0.76; n = 1,199 and HR, 0.63; 95% CI, 0.52 to 0.76; n = 1,917, respectively). Recommendations ADT plus docetaxel or abiraterone in newly diagnosed metastatic non-castrate prostate cancer offers a survival benefit as compared with ADT alone. The strongest evidence of benefit with docetaxel is in men with de novo high-volume (CHAARTED criteria) metastatic disease. Similar survival benefits are seen using abiraterone acetate in high-risk patients (LATITUDE criteria) and in the metastatic population in STAMPEDE. ADT plus abiraterone and ADT plus docetaxel have not been compared, and it is not known if some men benefit more from one regimen as opposed to the other. Fitness for chemotherapy, patient comorbidities, toxicity profiles, quality of life, drug availability, and cost should be considered in this decision. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .
引用
- Morris MJ, Rumble RB, Basch E, et al. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018. PMID: 29608397. doi:10.1200/JCO.2018.78.0619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。